Survival outcomes and treatment responses in study cohorts
| Outcome of interest . | All cohorts (N = 120) . | Front-line therapy (all therapies including ABVD) (N = 90) . | First-line ABVD only (N = 63) . | Relapsed/refractory therapy (including ASCT) (N = 29) . | Relapsed/refractory ASCT only (N = 18) . |
|---|---|---|---|---|---|
| 2-year overall survival | 90% [82-95%] n = 75 | 91% [86-96%] n = 56 | 93% [88-97%] n = 42 | 83% [72-89%] n = 19 | 83% [75-91%] n = 15 |
| 5-year overall survival | 84% [68-90%] n = 75 | 85% [72-91%] n = 60 | 87% [80-92%] n = 45 | 75% [58-84%] n = 15 | 76% [60-85%] n = 14 |
| 2-year progression-free survival | 78% [65-86%] n = 63 | 82% [76-88] n = 46 | 83% [77-88%] n = 37 | 61% [52-65%] n = 17 | 64% [57-69%] n = 14 |
| 5-year progression-free survival | 69% [55-80%] n = 64 | 77% [63-81%] n = 50 | 78% [69-82%] n = 39 | 51% [43-57%] n = 14 | 52% [45-58%] n = 13 |
| Complete response | 76% [70-84%] n = 41 | 62% [24-76%] n = 14 | |||
| Partial response | 13% [6-18%] n = 41 | 26% [5-35%] n = 14 | |||
| Stable disease | 1% [0-4%] n = 41 | 15% [7-24%] n = 14 | |||
| Progressive disease | 6% [3-10%] n = 41 | 11% [6-16%] n = 14 |
| Outcome of interest . | All cohorts (N = 120) . | Front-line therapy (all therapies including ABVD) (N = 90) . | First-line ABVD only (N = 63) . | Relapsed/refractory therapy (including ASCT) (N = 29) . | Relapsed/refractory ASCT only (N = 18) . |
|---|---|---|---|---|---|
| 2-year overall survival | 90% [82-95%] n = 75 | 91% [86-96%] n = 56 | 93% [88-97%] n = 42 | 83% [72-89%] n = 19 | 83% [75-91%] n = 15 |
| 5-year overall survival | 84% [68-90%] n = 75 | 85% [72-91%] n = 60 | 87% [80-92%] n = 45 | 75% [58-84%] n = 15 | 76% [60-85%] n = 14 |
| 2-year progression-free survival | 78% [65-86%] n = 63 | 82% [76-88] n = 46 | 83% [77-88%] n = 37 | 61% [52-65%] n = 17 | 64% [57-69%] n = 14 |
| 5-year progression-free survival | 69% [55-80%] n = 64 | 77% [63-81%] n = 50 | 78% [69-82%] n = 39 | 51% [43-57%] n = 14 | 52% [45-58%] n = 13 |
| Complete response | 76% [70-84%] n = 41 | 62% [24-76%] n = 14 | |||
| Partial response | 13% [6-18%] n = 41 | 26% [5-35%] n = 14 | |||
| Stable disease | 1% [0-4%] n = 41 | 15% [7-24%] n = 14 | |||
| Progressive disease | 6% [3-10%] n = 41 | 11% [6-16%] n = 14 |
Data for survival outcomes presented as median percentage of the outcome of interest followed by [interquartile range] and below each outcome is the number of studies reporting that specific endpoint.